[go: up one dir, main page]

PE20151435A1 - Laquinimod para reducir el dano talamico en la esclerosis multiple - Google Patents

Laquinimod para reducir el dano talamico en la esclerosis multiple

Info

Publication number
PE20151435A1
PE20151435A1 PE2015000472A PE2015000472A PE20151435A1 PE 20151435 A1 PE20151435 A1 PE 20151435A1 PE 2015000472 A PE2015000472 A PE 2015000472A PE 2015000472 A PE2015000472 A PE 2015000472A PE 20151435 A1 PE20151435 A1 PE 20151435A1
Authority
PE
Peru
Prior art keywords
laquinimod
multiple sclerosis
thalamic damage
reduce
damage
Prior art date
Application number
PE2015000472A
Other languages
English (en)
Inventor
Massimo Filippi
Giancarlo Comi
Maria Assunta Rocca
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PE20151435A1 publication Critical patent/PE20151435A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)

Abstract

La invencion proporciona metodos para inhibir o reducir el dano talamico en un sujeto, que comprende administrar laquinimod a un sujeto afectado con esclerosis multiple
PE2015000472A 2012-10-12 2013-10-09 Laquinimod para reducir el dano talamico en la esclerosis multiple PE20151435A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261713256P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
PE20151435A1 true PE20151435A1 (es) 2015-10-15

Family

ID=50475887

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000472A PE20151435A1 (es) 2012-10-12 2013-10-09 Laquinimod para reducir el dano talamico en la esclerosis multiple

Country Status (18)

Country Link
US (2) US20140107154A1 (es)
EP (1) EP2961406A4 (es)
JP (1) JP2015533163A (es)
KR (1) KR20150080509A (es)
CN (1) CN105263325A (es)
AR (1) AR092993A1 (es)
AU (2) AU2013329348A1 (es)
BR (1) BR112015007782A2 (es)
CA (1) CA2884272A1 (es)
CL (2) CL2015000732A1 (es)
EA (1) EA201590726A1 (es)
HK (1) HK1218865A1 (es)
IL (1) IL237745A0 (es)
MX (1) MX2015004564A (es)
PE (1) PE20151435A1 (es)
SG (1) SG11201501874TA (es)
TW (1) TW201420101A (es)
WO (1) WO2014058979A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
US9284276B2 (en) 2012-02-16 2016-03-15 Teva Pharmaceutical Industries, Ltd. N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CA2900503A1 (en) * 2013-02-15 2014-08-21 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
US20150174118A1 (en) * 2013-12-20 2015-06-25 Teva Pharmaceutical Industries, Ltd. Use of laquinimod to delay huntington's disease progression
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
KR20180006881A (ko) 2015-03-09 2018-01-19 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
SG10202102198RA (en) * 2016-09-13 2021-04-29 Intekrin Therapeutics Inc Treatment of multiple sclerosis with chs-131
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
US20090258847A1 (en) * 2006-07-17 2009-10-15 Erwin Paul Schreiner Cholanic Acid Amides
TW201438738A (zh) * 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
SI2442651T1 (sl) * 2009-06-19 2015-10-30 Teva Pharmaceutical Industries Ltd. Zdravljenje multiple skleroze z lakvinimodom
US9585878B2 (en) * 2009-08-10 2017-03-07 Teva Pharmaceutical Industries, Ltd. Treatment of BDNF-related disorders using laquinimod
US20130035390A1 (en) * 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
SG10201509831XA (en) * 2010-12-07 2015-12-30 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
ES2602794T3 (es) * 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
WO2013055907A1 (en) * 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途

Also Published As

Publication number Publication date
WO2014058979A8 (en) 2015-04-16
MX2015004564A (es) 2015-07-21
US20140107154A1 (en) 2014-04-17
TW201420101A (zh) 2014-06-01
AU2013329348A1 (en) 2015-05-28
EP2961406A2 (en) 2016-01-06
HK1218865A1 (zh) 2017-03-17
EP2961406A4 (en) 2017-01-04
CL2016002873A1 (es) 2017-04-17
JP2015533163A (ja) 2015-11-19
KR20150080509A (ko) 2015-07-09
AU2017203896A1 (en) 2017-06-29
EA201590726A1 (ru) 2015-10-30
AR092993A1 (es) 2015-05-13
WO2014058979A2 (en) 2014-04-17
IL237745A0 (en) 2015-05-31
BR112015007782A2 (pt) 2017-07-04
CN105263325A8 (zh) 2017-07-14
SG11201501874TA (en) 2015-05-28
WO2014058979A3 (en) 2015-08-20
CL2015000732A1 (es) 2015-08-07
US20160296511A1 (en) 2016-10-13
CN105263325A (zh) 2016-01-20
CA2884272A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
PE20151435A1 (es) Laquinimod para reducir el dano talamico en la esclerosis multiple
UY4230Q (es) Bocadillo retorcido para mascota
CR20110398S (es) Colchón
PH12014501653A1 (en) Metalloenzyme inhibitor compounds
UY4211Q (es) Pizarra para marcadores
UY34280A (es) Nuevos compuestos que tienen actividad inhibidora frente a la daminoacido oxidasa.
CL2014003534A1 (es) Metodo para reducir el riesgo de un evento cardiovascular en un sujeto en terapia con estatina.
UY34537A (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p
CL2014003515A1 (es) Composición herbicida que tiene actividad herbicida mejorada.
PH12015500900A1 (en) A stabilized pemetrexed formulation
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
EA201390616A1 (ru) ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
MX373239B (es) Mejoras en o con relacion a compuestos organicos.
IN2014DN11078A (es)
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
UY34038A (es) Esteres aromaticos para composiciones agroquimicas.
BR112014032501A2 (pt) composto, e, composição farmacêutica.
ITRM20120601A1 (it) Formatore di spalla.
MY175703A (en) Tablets with improved acceptance and good storage stability
UY4241Q (es) Mesa
ES2571402T3 (es) Producto mejorado para el cuidado de heridas
UY34755A (es) Agentes para el control de la glycaspis brimblecombei
UY34035A (es) Compuestos fungicidas relacionados con el 4,5-dihidroisoxazol.
CL2014002485A1 (es) Composición que comprende lactoferrina para prevenir, mejorar o tratar la diarrea.
CR20130615S (es) Contenedor

Legal Events

Date Code Title Description
FD Application declared void or lapsed